Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the Company will report clinical data from the Phase 1 study evaluating prulacabtagene leucel (prula-cel) as a potential treatment for patients with systemic lupus erythematosus with or without lupus nephritis on Monday, September 28, 2026. Following the announcement, the company will host a webcast presentation at 8:00am ET to discuss the results.